Comment
doi: 10.1016/j.jhep.2013.01.027.
Epub 2013 Jan 29.
Reply to: "usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis"
- PMID: 23376364
- DOI: 10.1016/j.jhep.2013.01.027
Item in Clipboard
Comment
Reply to: "usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis"
J Hepatol.
2013 Jun.
Free article
No abstract available
Comment on
-
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure.J Hepatol. 2013 Mar;58(3):488-94. doi: 10.1016/j.jhep.2012.11.013. Epub 2012 Nov 23. J Hepatol. 2013. PMID: 23183521 Clinical Trial.
-
Usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis.J Hepatol. 2013 Jun;58(6):1259. doi: 10.1016/j.jhep.2013.01.024. Epub 2013 Jan 29. J Hepatol. 2013. PMID: 23376359 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
